分子时代比利时成人型弥漫性胶质瘤的流行病学与生存分析
基于比利时全国人群癌症登记库,回顾2017至2019年2233例成人型弥漫性胶质瘤的组织学报告,并按IDH和1p/19q状态转换为2021年WHO分类。比利时年龄标化发病率为8.55/10万人年,4级病变为6.72/10万人年。IDH野生型胶质母细胞瘤中位总生存9.3个月,短于4级IDH突变型星形细胞瘤的25.9个月。
要点
- 比利时成人型弥漫性胶质瘤年龄标化发病率为8.55/10万人年。
- IDH野生型胶质母细胞瘤中位总生存9.3个月,4级IDH突变型星形细胞瘤为25.9个月。
- 2级和3级IDH突变型星形细胞瘤3年生存概率分别为86.0%和75.7%。
核心结论
- 该登记库研究基于已知分子状态的成人型弥漫性胶质瘤大型队列,提供真实世界生存数据,补充了目前主要基于历史 landmark 试验和较小回顾性队列研究的文献。
研究设计与样本
- 使用比利时全国人群癌症登记库,回顾2017年至2019年比利时诊断为成人型弥漫性胶质瘤的所有已知组织学报告。
- 将ICD-O-3形态学编码与组织学诊断匹配,并利用IDH和1p/19q突变状态将数据转换为2021年WHO中枢神经系统肿瘤分类。
主要发现
- 2017年至2019年比利时共诊断2233例成人型弥漫性胶质瘤,67.1%的病例可获得完整分子状态。
- 比利时成人型弥漫性胶质瘤年龄标化发病率为8.55/10万人年,4级病变为6.72/10万人年。
- IDH野生型胶质母细胞瘤中位总生存9.3个月,显著短于4级IDH突变型星形细胞瘤的中位生存25.9个月。
- 2级和3级IDH突变型星形细胞瘤的3年生存概率分别为86.0%和75.7%。
- IDH野生型星形细胞瘤预后更差,2级和3级病变的3年生存概率分别为31.6%和5.7%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Survival data of diffuse adult-type glioma is mostly based on prospective clinical trials or small retrospective cohort studies. Real-world data with large patient cohorts is currently lacking. METHODS: Using the nationwide, population-based Belgian Cancer Registry, all known histological reports of patients diagnosed with an adult-type diffuse glioma in Belgium between 2017 and 2019 were reviewed. The ICD-O-3 morphology codes were matched with the histological diagnosis. The gathered data were transformed into the 2021 World Health Organization classification of CNS tumors using the IDH- and 1p/19q-mutation status. RESULTS: Between 2017 and 2019, 2233 diffuse adult-type gliomas were diagnosed in Belgium. Full molecular status was available in 67.1% of identified cases. The age-standardized incidence rate of diffuse adult-type glioma in Belgium was estimated at 8.55 per 100 000 person-years and 6.72 per 100 000 person-years for grade 4 lesions. Median overall survival time in IDH-wild-type glioblastoma was 9.3 months, significantly shorter compared to grade 4 IDH-mutant astrocytoma (median survival time: 25.9 months). The 3-year survival probability was 86.0% and 75.7% for grades 2 and 3 IDH-mutated astrocytoma. IDH-wild-type astrocytoma has a worse prognosis with a 3-year survival probability of 31.6% for grade 2 and 5.7% for grade 3 lesions. CONCLUSIONS: This registry-based study presents a large cohort of adult-type diffuse glioma with known molecular status and uses real-world survival data. It adds to the current literature which is mainly based on historical landmark trials and smaller retrospective cohort studies.
引用
- Pinson H, Silversmit G, Vanhauwaert D, et al. Epidemiology and survival of adult-type diffuse glioma in Belgium during the molecular era. Neuro Oncol. 2024. PMID: 37651614. doi:10.1093/neuonc/noad158
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。